Therapeutic Antibody Development for Bladder Cancer
Bladder tumors that invade the muscularis propria often exhibit limited responsiveness to currently available therapeutic approaches, such as surgery and conventional chemotherapy. Antibody-based therapeutic strategies have emerged as an established treatment option for bladder cancer over the past decade. Alfa Cytology is equipped with extensive expertise in this field and is committed to assisting you and your teams in developing safe and efficacious therapeutic antibodies with utmost efficiency.
Fig.1 Antibody-based therapeutics for oncology. (Carter, P. J., et al., 2022)
Our Services
As a leading contract research organization, Alfa Cytology possesses extensive expertise in the development of optimized therapeutic antibodies. Our unique portfolio of integrated services enables us to provide comprehensive guidance throughout the entire journey of bladder cancer antibody drug discovery, ranging from target selection to preclinical drug candidates.
Monoclonal Antibody Development Service
We offer comprehensive monoclonal antibody (mAb) development, focusing on antigen identification, hybridoma technology, recombinant production, and rigorous in vitro and in vivo validation to ensure high specificity and efficacy in targeting bladder cancer cells.
Bispecific Antibody Development Service
Our bispecific antibody (bsAb) development involves designing antibodies that can target two different antigens simultaneously, utilizing advanced engineering techniques, conducting functional assays, to enhance therapeutic efficacy against bladder cancer.
ADC Development Service
In antibody-drug conjugate (ADC) development, we employ state-of-the-art conjugation techniques to attach cytotoxic drugs to antibodies, ensuring stability and efficacy, comprehensive toxicity evaluation, and detailed pharmacokinetic studies for targeted bladder cancer therapy.
Workflow of Therapeutic Antibody Development
Our comprehensive workflow ensures a streamlined and efficient process from discovery to optimization, designed to meet your specific research needs.
|
Antigen Selection Service
Our antigen selection service includes high-throughput screening and bioinformatics to identify potential bladder cancer targets, followed by rigorous validation processes such as tissue expression analysis and functional studies to confirm target relevance. |
Antibody Discovery Service
We generate high-affinity antibodies against selected antigens using hybridoma technology, phage display, and single B cell screening, ensuring rapid discovery of antibodies with high specificity and efficacy for bladder cancer treatment. |
|
 |
Antibody Engineering and Optimization Service
To enhance therapeutic potential, we offer affinity maturation, humanization, and Fc engineering to improve binding affinity, reduce immunogenicity, and optimize effector functions such as ADCC and CDC. |
Antibody Characterization Service
Our comprehensive characterization services include measuring binding affinity and specificity, conducting functional assays, assessing thermal and storage stability, and performing pharmacokinetic analysis. |
|
|
Contact Us
As a trusted partner in therapeutic antibody generation, Alfa Cytology is fully dedicated to contributing to the success of our customers' bladder cancer therapeutic projects. Contact us to support your therapeutic antibody discovery project and gain access to the most comprehensive solution for developing your antibody drug candidate.
Reference
- Carter, P. J., & Rajpal, A. Designing antibodies as therapeutics. Cell, 2022, 185(15), 2789–2805.
For research use only. Not intended for any clinical use.
Related Services
